China: a hot summer

In our May article (https://bsic.it/chinese-divergence-real-vs-financial/), we underlined how many difficulties China faced. We also analysed the development of a stock market bubble in the Shanghai Composite equity index (SHCOMP) and in the Shenzhen CSI 300 (SHSZ300) equity index. This summer saw that bubble bursting. The SHCOMP was trading at 3,185 Read more…

Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…